Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
NCT04596995 · UCB Biopharma SRL · PHASE3 · terminated · last registry update 2024-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic Business Decision; Not a safety decision” | – | Registry record, UCB Biopharma SRL |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FCGRT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-09Phase 3 first posted: Clinique Neuro-Outaouais, efgartigimod administration (NCT06765161)
- 2024-12-19Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT06741969)
- 2024-09-19Phase 3 first posted: University Health Network, Toronto, efgartigimod (NCT06587867)
- 2024-08-06Phase 3 first posted: UCB Biopharma SRL, rozanolixizumab (NCT06540144)
- 2024-08-01Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Intravenous immunoglobulins (IVIG) (NCT06533098)
- 2024-06-10Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT06449651)
- 2024-03-07Results posted on the registry: UCB Biopharma SRL, rozanolixizumab (NCT04828343)
- 2024-01-29Results posted on the registry: UCB Biopharma SRL, UCB7665 (NCT02718716)
- 2023-11-29Phase 3 first posted: UCB Biopharma SRL, rozanolixizumab (NCT06149559)
- 2023-08-21Results posted on the registry: UCB Biopharma SRL, Rozanolixizumab (NCT04124965)
- 2023-08-21Results posted on the registry: UCB Biopharma SRL, Rozanolixizumab (NCT03971422)
- 2023-08-08Results posted on the registry: UCB Biopharma SRL, Rozanolixizumab (NCT04200456)
- 2023-08-08Results posted on the registry: UCB Biopharma SRL, Rozanolixizumab (NCT04224688)
- 2023-08-08Also stopped (terminated): UCB Biopharma SRL, Rozanolixizumab (NCT04224688)
- 2023-07-14Results posted on the registry: argenx, ARGX-113 (NCT03770403)
- 2023-06-22Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT05912517)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision